Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2026-04-13 Major Shareholding Noti…
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Major Shareholder Announcement
Major Shareholding Notification Classification · 95% confidence The document is a ‘storaktionærmeddelelse’ (major shareholder notification) under Danish capital markets law, stating that Martin Bundgaard has crossed the 5% ownership threshold. This clearly matches the ‘Major Shareholding Notification’ category (Code: MRQ).
2026-04-13 Danish
Major Shareholder Announcement
Major Shareholding Notification Classification · 82% confidence The document is a “Storaktionær Meddelelse” under Danish Capital Markets Act §§30 and 38, announcing that an individual has crossed the 5% ownership threshold. This is a classic major shareholding notification (threshold crossing).
2026-04-13 Danish
Major Shareholder Announcement
Major Shareholding Notification Classification · 94% confidence The document is a Company Announcement under the Danish Capital Markets Act stating that a shareholder (Martin Bundgaard) has crossed the 5% ownership threshold and now holds 5.13% of BioPorto A/S voting rights. This is a notification of a change in significant shareholding levels (threshold crossing). Matches the definition of Major Shareholding Notification (Code: MRQ).
2026-04-13 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 99% confidence The document is a formal announcement under sections 30 and 38 of the Danish Capital Markets Act stating that Martin Bundgaard has exceeded the 5% threshold of share capital and voting rights, clearly notifying a change in significant share ownership. This matches the definition of a Major Shareholding Notification (MRQ).
2026-04-13 English
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
M&A Activity Classification · 88% confidence The document is a press release announcing BioPorto’s sale of its antibody business to Janel Life Sciences, detailing transaction terms (purchase price, earn‐out), strategic rationale, and updated financial guidance. This is a corporate divestiture/M&A transaction announcement rather than an earnings summary, management discussion, or regulatory notice. Therefore, it is classified under M&A Activity (Code: TAR).
2026-04-08 Danish
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
M&A Activity Classification · 80% confidence The document is a corporate press release announcing the sale (divestiture) of BioPorto’s antibody business to Janel Life Sciences, including transaction terms, strategic rationale, and updated financial guidance. This is a transaction announcement of an asset sale (M&A activity). Therefore it falls under M&A Activity (Code: TAR).
2026-04-08 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.